Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 6/20 | 0.40 |
| ▸ | RAB9A | P51151 | 6/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 7/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | CDK2 | P24941 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | NAMPT | P43490 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.35 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26242152 | 0.77 | DAO (0.43) | HCAR2NPC1RAB9ASMN1; SMN2TP53 | |
| SCHEMBL6533926 | 0.74 | HCAR2 (0.55) | HCAR2NPC1RAB9AALOX15SMN1; SMN2 | |
| SCHEMBL27130162 | 0.74 | HSD17B10 (0.52) | HCAR2NPC1RAB9AALOX15SMN1; SMN2 | |
| SCHEMBL20909207 | 0.72 | — | — | |
| SCHEMBL560682 | 0.72 | — | — | |
| SCHEMBL20897235 | 0.72 | DAO (0.66) | HCAR2DAO | |
| SCHEMBL23803932 | 0.71 | HCAR2 (0.47) | HCAR2NPC1RAB9AALOX15SMN1; SMN2 | |
| SCHEMBL28285927 | 0.69 | HCAR2 (0.53) | HCAR2NPC1RAB9AALOX15SMN1; SMN2 | |
| Water SCHEMBL28329906 | 0.69 | HCAR2 (0.53) | HCAR2NPC1RAB9AALOX15SMN1; SMN2 | |
| SCHEMBL4985098 | 0.68 | NPC1 (0.38) | HCAR2NPC1RAB9AALOX15SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11753400-B2 | D-amino acid oxidase inhibitors and therapeutic uses thereof | SYNEURX INTERNATIONAL (TAIWAN) CORP. (TW) | 2023-09-12 | — | — | US | disclosed |
| US-11753400-B2 | D-amino acid oxidase inhibitors and therapeutic uses thereof | SYNEURX INTERNATIONAL (TAIWAN) CORP. (TW) | 2023-09-12 | — | — | US | disclosed |
| US-20200331894-A1 | D-AMINO ACID OXIDASE INHIBITORS AND THERAPEUTIC USES THEREOF | SYNEURX INTERNATIONAL (TAIWAN) CORP. (TW) | 2020-10-22 | — | — | US | disclosed |
| US-10336724-B2 | D-amino acid oxidase inhibitors and therapeutic uses thereof | SYNEURX INTERNATIONAL (TAIWAN) CORP. (TW) | 2019-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200331894-A1 | D-AMINO ACID OXIDASE INHIBITORS AND THERAPEUTIC USES THEREOF | DAO, DDO, DDC | HCAR2 910/4885NPC1 3014/4885RAB9A 2735/4885 |
| US-11753400-B2 | D-amino acid oxidase inhibitors and therapeutic uses thereof | DAO, DDO, DDC | HCAR2 910/4885NPC1 3014/4885RAB9A 2735/4885 |
| US-10336724-B2 | D-amino acid oxidase inhibitors and therapeutic uses thereof | DAO, DDO, DDC | HCAR2 910/4885NPC1 3014/4885RAB9A 2735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.